Glaxo in €453m anti-clot deal

GlaxoSmithKline Plc, Europe’s biggest drug maker, said it agreed to buy two anti-blood clot treatments from France’s Sanofi-Synthelabo for €453 million ($544 million) in cash.

Glaxo, which is based in Brentford, England, will gain Sanofi’s Fraxiparine and Arixtra medicines along with a French manufacturing facility in the transaction.

The transaction in conditional on the completion of the takeover, Glaxo said.